Abstract
The oncogenic fusion protein E2A–HLF is a chimeric transcription factor that arises from the t(17;19) translocation in childhood B-cell acute lymphoblastic leukemias (B-precursor ALL) and is associated with very poor outcome. We show that retroviral-mediated expression of E2A–HLF alone is sufficient to immortalize primary lymphoid progenitors. We identify Lmo2 and Bcl-2 as direct target genes downstream of E2A–HLF. We use real-time PCR analysis to show that LMO2 and BCL-2 expression is preferentially upregulated both in biopsy material from t(17;19) B-precursor ALL patients and lymphoid cell lines derived from t(17;19) leukemias. Co-expression of Lmo2 and Bcl-2 was sufficient to immortalize lymphoid progenitor cells resulting in a similar phenotype to that induced by E2A–HLF alone. Both shRNA-mediated knockdown of Lmo2 expression and pharmacological inhibition of BCL-2 function in E2A–HLF immortalized cells severely compromised their viability. These data suggest that both Lmo2 and Bcl-2 are required for the action of E2A–HLF in leukemogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Raimondi SC, Privitera E, Williams DL, Look AT, Behm F, Rivera GK et al. New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. Blood 1991; 77: 2016–2022.
Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992; 257: 531–534.
Hunger SP, Ohyashiki K, Toyama K, Cleary ML . Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev 1992; 6: 1608–1620.
Hunger SP, Brown R, Cleary ML . DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t(17;19) acute lymphoblastic leukemia chimera E2A-HLF. Mol Cell Biol 1994; 14: 5986–5996.
Inaba T, Shapiro LH, Funabiki T, Sinclair AE, Jones BG, Ashmun RA et al. DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein. Mol Cell Biol 1994; 14: 3403–3413.
Yoshihara T, Inaba T, Shapiro LH, Kato JY, Look AT . E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF. Mol Cell Biol 1995; 15: 3247–3255.
Inukai T, Inaba T, Yoshihara T, Look AT . Cell transformation mediated by homodimeric E2A-HLF transcription factors. Mol Cell Biol 1997; 17: 1417–1424.
Inukai T, Inaba T, Ikushima S, Look AT . The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF. Mol Cell Biol 1998; 18: 6035–6043.
Seidel MG, Look AT . E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene 2001; 20: 5718–5725.
Smith KS, Rhee JW, Cleary ML . Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol Cell Biol 2002; 22: 7678–7687.
Smith KS, Chanda SK, Lingbeek M . Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Molecular Cell 2003; 12: 393–400.
Ayton PM, Cleary ML . Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298–2307.
Weinstein IB . Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 2002; 297: 63–64.
Huettner CS, Zhang P, Van Etten RA, Tenen DG . Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57–60.
Weinstein IB, Joe AK . Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract 2006; 3: 448–457.
Kurosawa H, Goi K, Inukai T, Inaba T, Chang KS, Shinjyo T et al. Two candidate downstream target genes for E2A-HLF. Blood 1999; 93: 321–332.
Inukai T, Inoue A, Kurosawa H, Goi K, Shinjyo T, Ozawa K et al. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 1999; 4: 343–352.
Dang J, Inukai T, Kurosawa H, Goi K, Inaba T, Lenny NT et al. The E2A-HLF oncoprotein activates Groucho-related genes and suppresses Runx1. Mol Cell Biol 2001; 21: 5935–5945.
Matsunaga T, Inaba T, Matsui H, Okuya M, Miyajima A, Inukai T et al. Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. Blood 2004; 103: 3185–3191.
Inaba T, Inukai T, Yoshihara T, Seyschab H, Ashmun RA, Canman CE et al. Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature 1996; 382: 541–544.
Yeung J, Kempski H, Neat M, Bailey S, Smith O, Brady HJ . Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients’ cells. Haematologica 2006; 91: 422–424.
Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288–296.
Yeung J, O’Sullivan E, Hubank M, Brady HJM . E4BP4 expression is regulated by the t(17;19)-associated oncoprotein E2A-HLF in pro-B cells. Br J Haematol 2004; 125: 560–567.
Morrow M, Horton S, Kioussis D, Brady HJM, Williams O . TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 2004; 103: 3890–3896.
Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289–1295.
Shojaei F, Trowbridge J, Gallacher L, Yuefei L, Goodale D, Karanu F et al. Hierarchial and ontogenic positions serve to define the molecular basis of human hematopoietic stem cell behavior. Dev Cell 2005; 8: 651–653.
Crable SC, Anderson KP . A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene. Blood 2003; 101: 4757–4764.
Nam CH, Rabbitts TH . The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol Ther 2006; 13: 15–25.
Kirkin V, Joos S, Zornig M . The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229–249.
Ohyashiki K, Fujieda H, Miyauchi J, Ohyashiki JH, Tauchi T, Saito M et al. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t (17;19) chromosomal translocation the growth of which is inhibited by Interleukin-3. Leukaemia 1991; 5: 322–331.
Takahashi H, Goto H, Funabiki T, Fujii H, Yamazaki S, Fujioka K et al. Expression of two types of E2A-HLF fusion proteins in YCUB-2, a novel cell line established from B-lineage leukemia with t(17;19). Leukaemia 2001; 15: 995–997.
Greaves MF, Wiemels J . Origin of translocations in childhood leukaemia. Nat Rev Cancer 2003; 3: 639–649.
Lavau C, Szilvassy SJ, Slany R, Cleary ML . Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226–4237.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681.
Land H, Parada LF, Weinberg RA . Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596–602.
Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987; 49: 465–475.
Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41–47.
Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Slany R . Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617–628.
Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood 2010; 116: 962–970.
Acknowledgements
We thank Professor Jean-Pierre Bourquin, Zurich, Switzerland, Professor Andy Hall, Newcastle, UK and Professor Martin Stanulla, Kiel, Germany for permission to use t(17;19) patient material. We are grateful to the staff of the ICH Gene Microarray Centre, Animal Facility and Flow Cytometry. We thank Dr J Ham for helpful comments and evaluation of the manuscript. We thank Abbott Laboratories for the gift of ABT-737. This work was funded by the Audrey Callaghan Fellowship, the Leukaemia Research Fund and Children with Leukaemia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Rights and permissions
About this article
Cite this article
de Boer, J., Yeung, J., Ellu, J. et al. The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. Leukemia 25, 321–330 (2011). https://doi.org/10.1038/leu.2010.253
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.253
Keywords
This article is cited by
-
B-lineage transcription factors and cooperating gene lesions required for leukemia development
Leukemia (2013)
-
LIM-domain-only proteins in cancer
Nature Reviews Cancer (2013)